Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

nab-paclitaxel

  • Home
  • nab-paclitaxel
Relacorilant Plus Nab-Paclitaxel: A New Standard for Platinum-Resistant Ovarian Cancer?
Posted inClinical Updates news OB/GYN & Women's Health Oncology Specialties

Relacorilant Plus Nab-Paclitaxel: A New Standard for Platinum-Resistant Ovarian Cancer?

Posted by MedXY By MedXY 08/03/2025
Relacorilant combined with nab-paclitaxel significantly improved progression-free and overall survival in platinum-resistant ovarian cancer, with a favorable safety profile, suggesting a potential new treatment standard.
Read More
Nab-Paclitaxel Plus Gemcitabine Outperforms mFOLFIRINOX and S-IROX as First-Line Therapy for Metastatic Pancreatic Cancer: Insights from the GENERATE (JCOG1611) Trial
Posted inClinical Updates news Oncology Specialties

Nab-Paclitaxel Plus Gemcitabine Outperforms mFOLFIRINOX and S-IROX as First-Line Therapy for Metastatic Pancreatic Cancer: Insights from the GENERATE (JCOG1611) Trial

Posted by MedXY By MedXY 08/01/2025
A large Japanese phase II/III trial shows nab-paclitaxel plus gemcitabine confers longer overall survival and better tolerability compared to mFOLFIRINOX and S-IROX in metastatic pancreatic cancer.
Read More
  • Brain Imaging Biomarkers and Cognitive Outcomes in a Multidomain Lifestyle Intervention: The POINTER Imaging Ancillary Study
  • Thyroid Hormones May Offer a New Therapeutic and Prognostic Angle in ADPKD
  • Time-Restricted Eating vs Dietetic Guidance for Glycaemic Outcomes in Adults at Risk of Type 2 Diabetes
  • Gestational Diabetes and Later Cancer Risk: Reassuring Overall Results, but a Kidney Cancer Signal Emerges
  • Publicly Funded Intermittently Scanned Continuous Glucose Monitoring Is Linked to Fewer Hospitalizations in Insulin-Treated Type 2 Diabetes
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health quality of life randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in